Genmab

Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
EP Vantage
cervical cancer
tisotumab vedotin
Genmab
Seattle Genetics
clinical trials
Flag link:
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
Fierce Biotech
AbbVie
bispecific antibodies
cancer
Genmab
Regeneron
epcoritamab
Flag link:
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
EP Vantage
Genmab
tisotumab vedotin
cervical cancer
Zogenix
Fintepla
Lennox-Gastaut Syndrome
Flag link:
A Look at 5 Big and Interesting Biotech IPOs for 2019
A Look at 5 Big and Interesting Biotech IPOs for 2019
BioSpace
IPOs
NASDAQ
Adaptive Biotechnologies
Genmab
Gossamer Bio
BridgeBio
Alector
Flag link:
[video] Genmab IPO raises $582m, becoming second largest US IPO ever by a bio-tech company
[video] Genmab IPO raises $582m, becoming second largest US IPO ever by a bio-tech company
Yahoo Finance
Genmab
IPOs
cancer
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M
Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M
Endpoints
Genmab
IPOs
cancer
Flag link:
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Yahoo/Benzinga
Merck
relebactam
TapImmune
earnings
JNJ
Seattle Genetics
Abbott Labs
Intuitive Surgical
Mirum Pharmaceuticals
Fulcrum Therapeutics
Genmab
Flag link:
Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap
Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap
Endpoints
Genmab
IPOs
NASDAQ
Flag link:
J&J bags $150M option on Genmab's Darzalex successor
J&J bags $150M option on Genmab's Darzalex successor
Fierce Biotech
Genmab
JNJ
Darzalex
Multiple Myeloma
drug development
Flag link:
Genmab files for $500M IPO to fund multi-front cancer R&D push
Genmab files for $500M IPO to fund multi-front cancer R&D push
Fierce Biotech
Genmab
IPOs
antibody-drug conjugate
cervical cancer
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
daratumumab
patents
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys
Janssen
Genmab
patent lawsuits
patents
Darazalex
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
patents
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys
Janssen
Genmab
Flag link:
Genmab's blockbuster Darzalex surpasses $2B in sales
Genmab's blockbuster Darzalex surpasses $2B in sales
BioCentury
Genmab
Multiple Myeloma
Darzalex
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Flag link:
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Flag link:
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:

Pages